Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood

Inclusion Criteria: * BMI between 25 and 42 kg/m2 * Diet-controlled diabetics, or diabetics on Metformin that have permission from Primacy Care Physician to wash-out of the drug for 6 weeks prior to the study and for the duration of the study * HbA1C between 6.0 - 7.9 (those on Metformin must have a HbA1c level below 7.5 prior to wash-out period) * Fasting Blood Glucose \< 150 mg/dl * Women must be post-menopausal or surgically sterile within age range * Subjects must live in vicinity of Stanford University Exclusion Criteria: * Prior Bariatric surgery * Personal or family history of medullary thyroid cancer * MEN2 Syndrome * Thyroid Nodules (not evaluated by PCP) * Pancreatitis (acute or chronic) * Gallstones * Fasting plasma triglycerides \> 400 mg/dl * Cardiovascular disease * Major organ disease * Unstable hypertension (BP \>160/100 mm Hg) * Heavy alcohol use * Self-reported weight change of \>2kg over past 6 weeks * Medication known to affect blood glucose, insulin sensitivity, or inflammation * NSAIDs (must cease use 4 weeks prior to study enrollment) * Previous use of liraglutide, Januvia, Byetta, or Lira.